Drug news
Pfizer and Astellas discontinue ENDEAR study ofXtandi (enzalutamide)for the treatment of triple-negative breast cancer.
Astellas has announced a joint decision with Pfizer to discontinue the planned ENDEAR trial comparing Xtandi (enzalutamide) in combination with paclitaxel chemotherapy or as monotherapy versus placebo with paclitaxel in triple-negative breast cancer. No patients were ever enrolled in the trial.
The companies have also decided that based on the enzalutamide data from the Phase II HER2+ and ER/PR+ breast cancer studies, there will not be follow-on Phase III studies at this time.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.